Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy ProgramsMIAMI, July 11, 2023 (GLOBE NEWSWIRE) -- Longeveron...
Neuroscience
BrainsWay Accelerates International Expansion in India
Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™BURLINGTON, Mass. and JERUSALEM, July 11, 2023...
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATIONSELECTED PROGRAMMES...
New Disease Modifying Drug for Alzheimer’s Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring
Vital breakthrough for Alzheimer's patients worldwide with Eisai's Leqembi FDA approval; Cognetivity Neurosciences' AI CognICA technology poised to play pivotal...
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
Company to voluntarily delist from the Toronto Stock Exchange (TSX)Last trading day on TSX will be July 21, 2023 TORONTO, Ontario...
Advanced FDA Cleared Magstim Horizon 3.0 Transcranial Magnetic Stimulation Now Available in United Kingdom
Approval by UKCA Empowers UK Physicians to Advance Care of Treatment Resistant Depression, Obsessive Compulsive Disorder, and Anxious Depression with...
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced...
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN), a biotechnology...
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readoutIRVINE, Calif.,...
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to...
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to...
Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
-- Represents the final step before submission of Investigational New Drug (IND) application to FDA, expected in the second half...
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMNRFXF) (“ProMIS” or...
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation
Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC...
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
Advisory committee voted 10 for and 4 against that evidence from the Phase III MOVE study show palovarotene is an...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development...
Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
Former Awardee and Artelo Employee, Professor Saoirse O’Sullivan will Present the 2023 Recipient with the AwardSOLANA BEACH, Calif., June 28,...
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer...